BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34255933)

  • 1. Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
    Takemoto S; Akagi K; Ono S; Tomono H; Honda N; Suyama T; Umeyama Y; Dotsu Y; Taniguchi H; Ogawara D; Senju H; Gyotoku H; Sugasaki N; Yamaguchi H; Nakatomi K; Fukuda M; Mukae H
    Thorac Cancer; 2021 Sep; 12(17):2300-2306. PubMed ID: 34255933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
    Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
    J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
    Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
    Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
    Sugawara S; Nakagawa K; Yamamoto N; Nokihara H; Ohe Y; Nishio M; Takahashi T; Goto K; Maemondo M; Ichinose Y; Seto T; Sakai H; Gemma A; Imamura F; Shingyoji M; Saka H; Inoue A; Takeda K; Okamoto I; Kiura K; Morita S; Tamura T
    Int J Clin Oncol; 2019 May; 24(5):485-493. PubMed ID: 30830659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
    Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
    Tamiya A; Morimoto M; Fukuda S; Naoki Y; Ibe T; Okishio K; Goto H; Yoshii A; Kita T; Nogami N; Fujita Y; Atagi S
    Invest New Drugs; 2018 Aug; 36(4):667-673. PubMed ID: 29572782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
    Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated 
with More Than Two Lines of Chemotherapy].
    Yin Y; Wu B; Huang Z; Zhuang W; Xu Z; Huang C; Huang Y; Zhang J
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):437-444. PubMed ID: 29945701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
    Yokoi T; Minami S; Shiroyama T; Koba T; Torii Y; Sugimoto H; Niki M; Mori M; Morimura O; Hirashima T; Komuta K; Kijima T
    Intern Med; 2019 May; 58(10):1405-1410. PubMed ID: 30713297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between Efficacy of Pemetrexed and EGFR Mutation Status for EGFR Mutated Lung Carcinoma].
    Kogure Y; Saka H; Imaizumi K
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):733-5. PubMed ID: 27306810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
    Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
    Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
    Nishiyama O; Taniguchi H; Kondoh Y; Takada K; Baba K; Saito H; Sugino Y; Yamamoto M; Ogasawara T; Kondo M; Imaizumi K; Hasegawa Y; Suzuki R; Shimokata K;
    Anticancer Drugs; 2011 Sep; 22(8):811-6. PubMed ID: 21317767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer.
    Zhao D; Feng JF; Wang XH
    Medicine (Baltimore); 2018 Jun; 97(22):e10740. PubMed ID: 29851779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.